Edgewise Therapeutics to Present at RBC Healthcare Conference on May 20
Event summary
- Edgewise Therapeutics will present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026, at 10:00 am ET.
- The presentation will be webcast live and available for replay for a limited time.
- Edgewise is developing Sevasemten for muscular dystrophies, EDG-7500 for hypertrophic cardiomyopathy, and EDG-15400 for heart failure.
- Behrad Derakhshan, Ph.D., Chief Operating Officer, and Maureen Franco, VP Corporate Communications, are the key contacts for investors and media.
The big picture
Edgewise Therapeutics is positioning itself as a key player in the muscle disease therapeutics space, with a focus on innovative treatments for muscular dystrophies and cardiac conditions. The upcoming presentation at the RBC Capital Markets Global Healthcare Conference is a strategic opportunity to showcase its pipeline and attract investor attention. The company's deep expertise in muscle physiology and its novel therapeutics could drive significant market interest and potential partnerships.
What we're watching
- Clinical Progress
- How the presentation will highlight the progress of Sevasemten in late-stage trials for Becker and Duchenne muscular dystrophies.
- Market Positioning
- Whether Edgewise can differentiate itself in the competitive landscape of muscle disease therapeutics.
- Investor Sentiment
- The impact of the presentation on investor confidence and potential stock movements.